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Background
We have previously established in a large retrospective
study that testing for microsatellite instability (MSI) in
colorectal cancer (CRC) from patients aged <60 years
was an effective first screen to identify individuals with
Lynch syndrome (LS). From these findings, MSI and/or
immunohistochemical (IHC) screening was recom-
mended for all newly diagnosed CRC patients aged <60
years in Western Australia, regardless of family history
of cancer. In the current study we evaluated the utility
of routine MSI/IHC screening by diagnostic pathology
laboratories for the detection of previously undiagnosed
individuals and families with LS.
From January 2009 to December 2010, 270 tumours
were tested for MSI and for expression of MLH1,
PMS2, MSH2 and MSH6 using IHC. Cases showing
MSI and/or loss of expression were also tested for the
BRAF V600E hotspot mutation. Seventy cases were
found to have MSI, of which 25 were excluded from
further investigation as possible LS cases due to pre-
sence of the BRAF V600E mutation. The remaining 45
“red flag” cases were eligible for germline testing based
on their MSI, IHC and BRAF status. From 26 cases
tested to date, 11 germline mutations have been found.
Nine were from individuals not previously recognized as
LS and two were untested members from known LS
families. Extrapolation of the mutation incidence (11/26,
42%) to all red flag cases (n=45) suggests that approxi-
mately 19 mutation carriers exist in this cohort. This
value approximates the number of LS cases that could
be expected to arise in the Western Australian popula-
tion over a two-year period (n=24), assuming that 1% of
all CRCs are due to LS.
Although further improvements in workflow can be
made, our preliminary findings following the implemen-
tation of state-wide routine MSI and IHC testing in
Western Australia indicate that the majority of LS cases
are being identified.
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